# Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment

> **NCT00337350** · PHASE4 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 20 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** rosiglitazone
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00337350
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-05-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00337350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00337350, "Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00337350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*